This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David S. Cooper, MD

JAMA. 1994;271(16):1283-1284.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

As noted by Schneider and colleagues¹ in this issue of THE JOURNAL, thyroid hormone (levothyroxine sodium) is one of the most frequently prescribed drugs in the United States. Postmenopausal women are particularly prone to develop hypothyroidism, thyroid nodules, and thyroid cancers and are therefore far more likely than men to be taking thyroid hormone, either for replacement therapy or suppression therapy.² Unfortunately, older women are also at high risk for progressive bone loss from thyroid hormone, as documented in a number of previous studies and summarized in the article by Schneider et al.¹ The risk of bone loss is greatest in those women taking larger thyroid hormone doses and seems to be minimal in women taking more modest doses.¹ Although the degree of skeletal demineralization observed in many studies places some patients below the fracture threshold in terms of their bone density, no study to date . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Endocrinology, Sinai Hospital of Baltimore (Md) and The Johns Hopkins University School of Medicine. Dr Cooper is a Contributing Editor of JAMA.

Footnotes
Reprint requests to Division of Endocrinology, Sinai Hospital of Baltimore, Belvedere at Greenspring, Baltimore, MD 21215 (Dr Cooper).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?